Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$2.73
-5.1%
$2.36
$1.60
$17.55
$77.70M1.87383,894 shs117,411 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$1.02
-2.9%
$1.31
$0.95
$4.44
$17.91M0.9156,357 shs34,896 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$7.05
-2.5%
$9.85
$6.53
$30.60
$61.56M2.89146,444 shs67,071 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.45
+1.4%
$1.38
$1.02
$9.29
$82.06M1.06401,871 shs369,502 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-5.05%-5.05%+13.07%-1.80%-77.81%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-2.86%+6.25%-16.39%-34.19%-69.91%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-2.49%-8.44%-24.27%-51.58%-62.08%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+1.40%+9.85%-9.38%-28.22%-83.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.2888 of 5 stars
3.33.00.00.03.10.80.6
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
2.7301 of 5 stars
3.53.00.00.03.31.70.6
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
2.8742 of 5 stars
2.91.00.04.62.00.80.0
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.3 of 5 stars
4.51.00.00.02.73.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.57
Moderate Buy$15.40465.14% Upside
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
3.00
Buy$7.00586.27% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.80
Reduce$73.67944.92% Upside
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80437.93% Upside

Current Analyst Ratings Breakdown

Latest LEXX, TCRX, MCRB, and ANRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
5/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
5/6/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
4/8/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/7/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
3/21/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/20/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
3/14/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$20.00 ➝ $15.00
3/14/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$10.00
3/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$14.00 ➝ $3.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$525.92K34.05N/AN/A$0.48 per share2.13
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.33M0.49N/AN/A($0.35) per share-20.14
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$4.42M18.56N/AN/A$3.15 per share0.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$36.31M-$2.34N/AN/AN/AN/A-49.28%-33.52%8/12/2025 (Estimated)
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$5.80M-$0.59N/AN/AN/A-1,473.04%-88.88%-83.59%7/11/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%8/12/2025 (Estimated)
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$89.22M-$1.09N/AN/AN/A-1,188.88%-58.72%-36.02%8/11/2025 (Estimated)

Latest LEXX, TCRX, MCRB, and ANRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.59-$0.53+$0.06-$0.56N/AN/A
5/12/2025Q1 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
4/14/2025Q2 2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$0.16-$0.15+$0.01-$0.15$0.14 million$0.17 million
3/20/2025Q4 2024
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.65-$0.56+$0.09-$0.56N/AN/A
3/5/2025Q4 2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.27-$0.29-$0.02-$0.30$1.43 million$0.67 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.05
13.10
13.09
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/A
29.62
29.62
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
1.12
1.12
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.13
9.56
9.56

Institutional Ownership

CompanyInstitutional Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
13.06%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
11.13%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
26.40%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A27.07 millionN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
717.56 million12.92 millionNot Optionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million162.03 millionOptionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million51.90 millionNot Optionable

Recent News About These Companies

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alto Neuroscience stock logo

Alto Neuroscience NYSE:ANRO

$2.72 -0.15 (-5.05%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$2.72 0.00 (-0.18%)
As of 05:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Lexaria Bioscience stock logo

Lexaria Bioscience NASDAQ:LEXX

$1.02 -0.03 (-2.86%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.03 +0.01 (+1.47%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$7.05 -0.18 (-2.49%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$7.09 +0.04 (+0.62%)
As of 05/28/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.45 +0.02 (+1.40%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.44 -0.01 (-1.03%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.